Depomed Inc (DEPO)

10.60
NASDAQ : Health Care
Prev Close 10.63
Day Low/High 10.54 / 10.83
52 Wk Low/High 9.38 / 27.02
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 62.96M
Market Cap 669.29M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

A review of data produced by BoardEx reveals that many big and small activist-targeted corporate boards feature young directors in their early-to-mid 30s who work for insurgent fund managers

Depomed Announces Corporate Governance Updates

Sets Date of 2017 Annual Meeting of Shareholders

Depomed Focuses on Flagship Drug Rather Than M&A: CEO

Depomed Focuses on Flagship Drug Rather Than M&A: CEO

The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Depomed unveiled steps the company is taking to shore itself up.

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.

Bearish Bets: A Furniture Retailer, a Logistics Firm and Other Stocks That Look Good Short

CYBE, TIS, HUBG, DEPO and ETH all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, BOOM, BWA, DAR, EHTH, ESRT, ETR, FNGN, FOE, FPO, FSS, GGG, KKR, KRA, MSCC, TOT, TZOO, WMAR Downgrades: BABY, CREG, DEPO, ETH, EXPE, GNRC, SPOK, TDC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

First Week of December 15th Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options begin trading this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Depomed Announces Appointment Of Sharon D. Larkin As Senior Vice President, Human Resources And Administration

Former Abbott Executive Brings Over 25 Years of Pharmaceutical Industry Experience

Depomed Enters Oversold Territory (DEPO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Sage Therapeutics, Depomed and NantKwest were among the biotech stock movers in premarket trading on Friday.

Depomed is Now Oversold (DEPO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Depomed Switches Out CEO and Board in Making Peace With Activist Starboard

Depomed Switches Out CEO and Board in Making Peace With Activist Starboard

Depomed settles with activist investor Starboard and replaces its CEO and two board members.

Senator McCaskill Launching Investigation Into Opioid Drugmakers

Senator McCaskill Launching Investigation Into Opioid Drugmakers

The U.S. Centers for Disease Control and Prevention says 91 Americans die every day as a result of an overdose.

CFO Says Depomed to Buy or Be Sold

CFO Says Depomed to Buy or Be Sold

The biotech company will either pick up assets to grow or sell itself to a larger company in the space, its chief financial officer told a conference.

First Week Of May 19th Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

First Week of April 21st Options Trading For Depomed (DEPO)

Investors in Depomed Inc saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new April 21st contracts and identified one put and one call contract of particular interest.

Argos Plummets 72%, Leads Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Also falling was Global Blood Therapeutics.

Depomed Reports 33% Increase in 2016 Net Product Sales

Depomed Reports 33% Increase in 2016 Net Product Sales

While companies in the opiod sector have had to deal with headlines about abuse as well as pharma pricing controversies, Depomed reported increased sales across its product line.